Literature DB >> 23537609

Liver receptor homologue-1 expression in ovarian epithelial and granulosa cell tumours.

Ashwini L Chand1, Niroshani Pathirage, Kyren Lazarus, Simon Chu, Ann E Drummond, Peter J Fuller, Colin D Clyne.   

Abstract

Granulosa cell tumours of the ovary (GCT) express aromatase and produce oestrogens. The ovarian-specific aromatase promoter (pII) is regulated by members of the group 5A nuclear receptor family, SF-1 and LRH-1. Since both SF-1 and LRH-1 are implicated in proliferation and cancer, we hypothesised that alteration in the expression of either or both receptors may be associated with GCT. We therefore determined the expression of LRH-1, SF-1 and aromatase in a cohort of GCT, mucinous and serous cystadenocarcinomas, and normal ovaries. LRH-1 mRNA was present at low level in normal ovary and serous cystadenocarcinoma, but was elevated approximately 30-fold in GCT, and 8-fold in mucinous cystadenocarcinoma, compared to normal ovary. LRH-1 protein expression was confirmed in GCT by immunohistochemistry. SF-1 mRNA was significantly lower that of LRH-1 in all samples and not significantly altered in GCT, compared to normal ovary. Aromatase mRNA was present at low level in normal ovary and serous and mucinous cystadenocarcinoma, and significantly elevated (18-fold) in GCT compared to normal ovary. Despite the coordinate over-expression of both LRH-1 and aromatase in GCT versus normal ovary, their levels did not correlate in individual patients; rather, aromatase expression correlated with that of SF-1. Finally, although both LRH-1 and SF-1 activated aromatase promoter activity in transient transfection studies, gel-shift and chromatin immunoprecipitation data indicated that SF-1, but not LRH-1, bound to the aromatase promoter. We conclude that SF-1 regulates aromatase expression in GCT; over-expression of LRH-1 suggests that this receptor may be involved in the pathogenesis of GCT by mechanisms other than the regulation of aromatase. Its role in this disease therefore warrants further investigation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23537609     DOI: 10.1016/j.steroids.2013.03.001

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  6 in total

1.  SERBP1 Is a Component of the Liver Receptor Homologue-1 Transcriptional Complex.

Authors:  Yelenis Mari; Graham M West; Catherina Scharager-Tapia; Bruce D Pascal; Ruben D Garcia-Ordonez; Patrick R Griffin
Journal:  J Proteome Res       Date:  2015-10-07       Impact factor: 4.466

2.  Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor.

Authors:  Zhuo-ying Hu; Liang-dan Tang; Hong-yu Zhang; Jing-ya Niu; Meng Lou
Journal:  Tumour Biol       Date:  2015-01-22

3.  LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21.

Authors:  Lijia Xiao; Yuliang Wang; Weicheng Liang; Liping Liu; Nannan Pan; Huimin Deng; Luqian Li; Chang Zou; Franky Leung Chan; Yiwen Zhou
Journal:  Cancer Manag Res       Date:  2018-08-01       Impact factor: 3.989

Review 4.  Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.

Authors:  Jianfu Zhou; Yuliang Wang; Dinglan Wu; Shusheng Wang; Zhiqiang Chen; Songtao Xiang; Franky Leung Chan
Journal:  Oncogene       Date:  2021-03-09       Impact factor: 9.867

5.  LRH-1 high expression in the ovarian granulosa cells of PCOS patients.

Authors:  Xiao Yang; Qiumin Wang; Ying Wang; Tian Song; Yanjun Zheng; Wenqi Wang; Yuhua Shi
Journal:  Endocrine       Date:  2021-06-15       Impact factor: 3.633

6.  Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.

Authors:  Yuka Hattori; Shizuka Yamada; Makoto Yamamoto; Makoto Orisaka; Tetsuya Mizutani; Yoshio Yoshida
Journal:  J Ovarian Res       Date:  2015-11-14       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.